Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi During the COVID-19 Pandemic and Neuromyelitis Optica Therapy, Treatment Options for Patients with Neuromyelitis Optica Spectrum Disorder
*Corresponding Author: Uqbah Iqbal, Department of Neuroimmunology, Aristotle University of Thessaloniki, Thessaloniki, Greece, Email: Iqbal_U@gmail.comReceived Date: Apr 05, 2023 / Published Date: May 30, 2023
Citation: Iqbal U (2023) During the COVID-19 Pandemic and Neuromyelitis Optica Therapy, Treatment Options for Patients with Neuromyelitis Optica Spectrum Disorder. J Clin Exp Neuroimmunol 8: 179.
Copyright: © 2023 Iqbal U. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
| Peer-reviewed Full Article 
Abstract
Neuromyelitis Optica (NMO) or device disease is a central nervous system inflammatory disorder characterized by optic neuritis and transverse myelitis episodes. In 1894, a doctor in Lyon, France, named Eugene device, described the condition. Afterward, it was thought that there was no clinical involvement beyond the optic nerve and spinal cord and that the disorder might be a variant of Acute Disseminated Encephalomyelitis (ADEM) when monophasic and a variant of classic Multiple Sclerosis (MS) when relapsing. However, NMO cases have frequently been associated with symptoms in other neurological axes.
